Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Germ Cell Tumors Clinical Trials

A listing of Germ Cell Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (14) clinical trials

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Patients with metastatic germ cell cancer and relapse after two or more courses of cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and no curative options. Taxanes in various combinations unfold cytotoxic effects on germ cell tumors resistant to conventional doses of cisplatin. Paclitaxel in combination with ifosfamide ...

Phase

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing and limited peripheral neuro-toxicity, two major potential advantages in patients with advanced NSGCTs. Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have demonstrated activity in pre-treated GCTs and are now part of ...

Phase

Study of Individuals and Families at High Risk for Testicular Cancer

OBJECTIVES: - Identify new families with familial testicular germ cell tumors (TGCT). - Determine the clinical features of familial TGCT. - Determine the underlying genetic mechanism for susceptibility to familial TGCT. - Determine the various parameters related to psychosocial and behavioral issues resulting from being a member of a family ...

Phase N/A

Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy

Germ cell tumors, a relatively rare disease, but most common malignancy in young males, occur most frequently in testis. The incidence is about 1%, but is increasing in the majority of developed countries. The testicular cancer is an extremely important oncological condition due to his high rate of 80-90% of ...

Phase

Trial of Gemcitabine Cisplatin and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors

This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted favorable prognosis.

Phase

Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors

Background The prognosis of pts who have failed multiple chemotherapy (CT) regimens is quite dismal. PD-L1 is frequently expressed by immunohistochemistry (IHC) in germ cell tumors (GCT). D is a monoclonal antibody (mAb) that inhibits the binding of PD-L1. T, an anti-CTLA4 mAb, is an immunomodulatory therapy. Combination immunotherapy has ...

Phase

Avelumab in Refractory Testicular Germ Cell Cancer.

Germ-cell tumours (GCTs) are extraordinarily chemosensitive and resemble the clinical and biological characteristics of a model for the cure of cancer. Nonetheless, a small proportion of patients do not have a durable complete remission (CR) with initial chemotherapy. Only 20-40% of them will be cured with the use of platinum-containing ...

Phase

Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors

Identification of late-effects through questionnaires and linkage to national registries. DNA samples will be gathered through buccal swabs or saliva kits and analysed with whole exome-sequencing.

Phase N/A

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

The study is an international collaboration with European sites. Collaborators on the study include the National Cancer Institute, the European Organization for Research and Treatment of Cancer and the Movember Foundation. Randomization will be stratified by region (North America and Europe) and by modified IPFSG (International Prognostic Factor Study Group) ...

Phase

First Line TIP in Poor Prognosis TGCTs.

Cycle 1: BEP regimen Serum tumor markers at day 18-21: Patients with an unfavorable pattern of tumor marker decrease after 1 cycle of BEP will receive 4 more cycles of TIP. TIP regimen: Taxol 250 mg/ m2 iv on day 1 Ifosfamid 1,2 g/ m2/ day iv x 5 days ...

Phase